Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress

October 9, 2018

BERKELEY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada). Data will be presented in three individual sessions with data for advanced melanoma patients who are naïve to anti-PD-1 therapy being presented as a late-breaking abstract poster discussion, at the European Society for Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018 in Munich Germany.

The details of the poster presentations and discussion sessions are as follows:

**Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)**

- **Poster Discussion Session:** Head and Neck Cancers
- **Final Publication Number:** 1050PD
- **Discussion Session Date/Time:** Saturday, October 20, 2018, 3:00 PM - 4:15 PM CEST
- **Discussion Session Location:** Hall B3 - Room 23, ICM München, Munich Germany
- **Poster Session Date/Time:** Saturday, October 20, 9:00 AM CEST to Monday, October 22, 5:00 PM CEST
- **Poster Session Location:** Hall B4 – ICM München, Munich Germany

**Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy**

- **Poster Discussion Session:** Melanoma and Other Skin Tumours
- **Final Publication Number:** LBA45
- **Discussion Session Date/Time:** Saturday, October 20, 2018, 2:45 PM - 4:05 PM CEST
- **Discussion Session Location:** ICM - Room 14b, ICM München, Munich Germany
- **Poster Session Date/Time:** Saturday, October 20, 2:45 PM CEST to Monday, October 22, 5:00 PM CEST
- **Poster Session Location:** Hall B4 – ICM München, Munich Germany

**Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after anti-PD-1 therapy**

- **Poster Session:** Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
- **Final Publication Number:** 1265P
- **Poster Session Date/Time:** Sunday, October 21, 12:45 PM - 1:45 PM CEST
- **Poster Session Location:** Hall A3 – Poster Area Networking Hub, ICM München, Munich Germany

**About SD-101**

SD-101, the Company's lead clinical candidate, is a proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. Dynavax is evaluating this intratumoral TLR9 agonist in several clinical studies to assess its safety and activity, including a Phase 2 study in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced melanoma and in patients with head and neck squamous cell cancer, in a clinical collaboration with Merck. Dynavax maintains all commercial rights to SD-101.

**About Dynavax**

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in January 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.